- 文献引用 : 2
|Application ||WB, DB, IHC-P, E|
|Calculated MW||18119 Da|
|Other Names||Cyclin-dependent kinase inhibitor 1, CDK-interacting protein 1, Melanoma differentiation-associated protein 6, MDA-6, p21, CDKN1A, CAP20, CDKN1, CIP1, MDA6, PIC1, SDI1, WAF1|
|Target/Specificity||This P21CIP1 Antibody is generated from rabbits immunized with a KLH conjugated synthetic phosphopeptide corresponding to amino acid residues surrounding T145 of human P21CIP1.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is first purified by protein A affinity chromatography. Then, the antibody fraction is peptide affinity purified in a 2-step procedure with peptides. The antibody is eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||Phospho-P21CIP1(T145) Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Synonyms||CAP20, CDKN1, CIP1, MDA6, PIC1, SDI1, WA|
|Function||May be involved in p53/TP53 mediated inhibition of cellular proliferation in response to DNA damage. Binds to and inhibits cyclin-dependent kinase activity, preventing phosphorylation of critical cyclin-dependent kinase substrates and blocking cell cycle progression. Functions in the nuclear localization and assembly of cyclin D-CDK4 complex and promotes its kinase activity towards RB1. At higher stoichiometric ratios, inhibits the kinase activity of the cyclin D-CDK4 complex. Inhibits DNA synthesis by DNA polymerase delta by competing with POLD3 for PCNA binding (PubMed:11595739).|
|Cellular Location||Cytoplasm. Nucleus.|
|Tissue Location||Expressed in all adult tissues, with 5-fold lower levels observed in the brain|
Author : Jou YJ1, Hua CH2, Lin CS3, Wang CY4, Wan L5, Lin YJ6, Huang SH7, Lin CW8,9.
Molecules. 2016 May 7;21(5). pii: E601. doi: 10.3390/molecules21050601.
Author : Marqués M1, Kumar A, Poveda AM, Zuluaga S, Hernández C, Jackson S, Pasero P, Carrera AC.
Proc Natl Acad Sci U S A. 2009 May 5;106(18):7525-30. doi: 10.1073/pnas.0812000106. Epub 2009 Apr 22.
Provided below are standard protocols that you may find useful for product applications.
P21CIP1 is a potent cyclin-dependent kinase inhibitor. This protein binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes, and thus functions as a regulator of cell cycle progression at G1. Expression is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. P21CIP1 can interact with proliferating cell nuclear antigen (PCNA), a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair. This protein has been reported to be specifically cleaved by CASP3-like caspases, which thus leads to a dramatic activation of CDK2, and may be instrumental in the execution of apoptosis following caspase activation.
Scott, S.A., et al., Leuk. Res. 28(12):1293-1301 (2004).
Amini, S., et al., J. Biol. Chem. 279(44):46046-46056 (2004).
Chen, T., et al., Cancer Res. 64(20):7412-7419 (2004).
Sieburg, M., et al., J. Virol. 78(19):10399-10409 (2004).
Giraud, S., et al., Oncogene 23(44):7391-7398 (2004).